San Diego, CA, United States of America

Philip Jochelson

This inventor holds 19 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents, primarily in Pharmacology. Top assignees: Currax Pharmaceuticals LLC, Pernix Sleep, Inc., Procom One, Inc.. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philip Jochelson. Retrieved from https://idiyas.com/inventor/philip-jochelson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 35(Granted Patents)


Company Filing History:


Years Active: 2011-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Low-Dose Doxepin
Sleep Disorders
Pharmacokinetics
Formulations
Insomnia Treatment
Combination Therapy
Elderly Patients
Ultra Low Dose
Methods of Use
Doxepin
Therapeutic Applications
Sleep Improvement
19 patents (USPTO):Explore Patents

Title: Innovations in Sleep Medicine: The Contributions of Philip Jochelson

Introduction: Philip Jochelson, based in San Diego, California, is a notable inventor in the field of sleep medicine, boasting an impressive portfolio of 19 patents. His work primarily focuses on methods for improving sleep quality, particularly through the use of low-dose doxepin, a medication that has shown significant promise in treating sleep disorders.

Latest Patents: Jochelson's latest patents include innovative methods for utilizing low-dose doxepin to enhance sleep efficacy. One of his remarkable patents details methods of preventing early awakenings and improving sleep efficiency during the crucial hours of 7 and 8 of sleep by administering low doses, specifically between 1-6 mg. Another notable invention addresses the unique challenges faced by elderly patients, specifically those aged 65 and older. His research indicates that administering initial daily dosages of doxepin ranging from 1-3 mg can effectively treat insomnia and related sleep disorders. These ultra-low dosages have been found to significantly decrease wake time during sleep and improve the overall sleep cycle, especially in the last hour of an 8-hour sleep duration, while ensuring safety for elderly individuals.

Career Highlights: Throughout his career, Philip Jochelson has made impactful contributions to the pharmaceutical sector by working with prestigious companies such as Pernix Sleep, Inc. and Currax Pharmaceuticals LLC. His dedication to developing effective solutions for sleep disorders has not only advanced the field of sleep medicine but has also enhanced the quality of life for many individuals suffering from these conditions.

Collaborations: Jochelson has collaborated with esteemed colleagues such as Roberta L. Rogowski and Susan E. Dubé. Together, they have worked on various projects aimed at refining treatment methodologies for sleep disorders, thereby furthering innovations in this critical area of health.

Conclusion: Philip Jochelson's contributions to the field of sleep medicine through his innovative patents and collaborative efforts exemplify the importance of research and development in addressing common health issues. His work continues to pave the way for more effective treatments for sleep disorders, especially among the elderly, ensuring that better sleep health is within reach for many.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…